ABHD5: The Abhydrolase Domain Containing 5 Protein (G51099)

Target Name: ABHD5

NCBI ID: G51099

ABHD5

ABHD5: The Abhydrolase Domain Containing 5 Protein

ABHD5 is a protein that has been identified as a potential drug target or biomarker for the treatment of various diseases, including diabetes, cardiovascular diseases, and neurodegenerative disorders. The protein is part of the superfamily of hydrolases, which are a group of enzymes that catalyze the breakdown of water molecules into hydrogen peroxide and other reactive oxygen species. ABHD5 is a member of the hydrolase 5 family, which is characterized by the presence of a unique transmembrane domain called the abhydrolase domain.

The abhydrolase domain is a small protein domain that is located at the N-terminus of ABHD5. It consists of a catalytic active site, a transmembrane region, and a C-terminus region that is involved in protein-protein interactions and other non-catalytic functions. The abhydrolase domain is responsible for the catalytic activity of ABHD5, which involves the hydrolysis of a wide variety of substrates, including nucleic acids, proteins, and other macromolecules.

Disease-related functions of ABHD5

ABHD5 has been shown to be involved in various diseases and disorders, including diabetes, cardiovascular diseases, and neurodegenerative disorders.

1. Diabetes:

ABHD5 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism in the Diabetes Zebrafish model. Studies have shown that ABHD5 can enhance the sensitivity of insulin-induced glucose uptake in the Diabetes Zebrafish model, indicating that it may play a role in the development and progression of diabetes.

1. Cardiovascular diseases:

ABHD5 has been shown to be involved in the regulation of inflammation and fibrosis in the cardiovascular system. Studies have shown that ABHD5 can promote the recruitment of immune cells to the site of inflammation and contribute to the development of fibrosis in the cardiovascular system.

1. Neurodegenerative disorders:

ABHD5 has been shown to be involved in the regulation of neurodegeneration in various models, including the neurotoxicity of amyloid peptides and the neurofibrillary tangles in Alzheimer's disease. Studies have shown that ABHD5 can protect against neurodegeneration in the neurotoxicity model and promote neurogenesis in the hippocampus, indicating that it may be a potential therapeutic target for the treatment of neurodegenerative disorders.

Targeting ABHD5

The abhydrolase domain of ABHD5 makes it a promising target for small molecule inhibitors. Several studies have shown that ABHD5 can be inhibited by various small molecules, including inhibitors of the abhydrolase domain itself, such as S4985 and MK-8628, as well as inhibitors of the activity of the enzyme itself, such as the drug QIIP-200 and the peptide fragment Enteroclostomus haematodes.

In addition to small molecule inhibitors, several structural studies have also shown that ABHD5 can interact with certain protein partners, including the protein casein and the nucleic acid protein SIRT1. These interactions may be important for the regulation of ABHD5 activity and could be a potential source of new therapeutic targets.

Conclusion

ABHD5 is a protein that has been shown to be involved in a variety of diseases and disorders, including diabetes, cardiovascular diseases, and neurodegenerative disorders. The abhydrolase domain of ABHD5 makes it a promising target for small molecule inhibitors and may be a valuable diagnostic or therapeutic tool for the treatment of these diseases. Further research is needed to fully understand the role of ABHD5 in disease and to develop effective therapies

Protein Name: Abhydrolase Domain Containing 5, Lysophosphatidic Acid Acyltransferase

Functions: Coenzyme A-dependent lysophosphatidic acid acyltransferase that catalyzes the transfert of an acyl group on a lysophosphatidic acid (PubMed:18606822). Functions preferentially with 1-oleoyl-lysophosphatidic acid followed by 1-palmitoyl-lysophosphatidic acid, 1-stearoyl-lysophosphatidic acid and 1-arachidonoyl-lysophosphatidic acid as lipid acceptor. Functions preferentially with arachidonoyl-CoA followed by oleoyl-CoA as acyl group donors (By similarity). Functions in phosphatidic acid biosynthesis (PubMed:18606822). May regulate the cellular storage of triacylglycerol through activation of the phospholipase PNPLA2 (PubMed:16679289). Involved in keratinocyte differentiation (PubMed:18832586). Regulates lipid droplet fusion (By similarity)

The "ABHD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets